Monday, March 26, 2012 8:00:31 AM
CTD Holdings, Inc. - NanoSonic Products Division Signs Exclusive Distribution Agreement With Uno Healthcare
Press Release: CTD Holdings, Inc. – 7 minutes agoShare0EmailPrintCompanies:CTD Holdings Inc.RELATED QUOTESSymbol Price Change
CTDH.OB 0.19 0.00
ALACHUA, Fla., March 26, 2012 (GLOBE NEWSWIRE) -- NanoSonic Products, Inc., a wholly owned subsidiary of CTD Holdings, Inc. (OTCQB:CTDH.OB - News), announced that the Company has signed an exclusive distribution agreement with Uno Healthcare of Miami, FL for its Trappsol Cyclo products in the territories of Brazil and Columbia, South America. Trappsol Cyclo is designated as an orphan drug for the treatment of Niemann Pick Type-C disease, also known as Childhood Alzheimer's, which affects children and adults resulting in progressive neurological degeneration.
"Uno Healthcare is a leader in the distribution of specialty pharmaceuticals in South American markets," stated NanoSonic Products President and CEO, Dr. Jeffrey Tate, "This agreement reinforces our commitment to be sure that Trappsol Cyclo gets to the sick children who will benefit from its use."
Trappsol Cyclo is the world's only API-grade cyclodextrin product. As it develops, it will be the lead product for Sphingo Biotechnology, Inc. another wholly owned division of CTD Holdings, Inc. exclusively focused on the development of API-grade cyclodextrins for pharmaceutical applications.
To receive timely information on CTD Holdings, Inc. when it hits the newswire, sign up for CTD Holdings' email news alert system today at: www.ctd-holdings.com/alert
About NanoSonic Products, Inc.:
NanoSonic Products, Inc. is part of the CTD Holdings, Inc. family of companies. CTD Holdings companies manufacture and market Trappsol and Aquaplex cyclodextrins and cyclodextrin complexes for food, nutrition and pharmaceutical markets. NanoSonic Products, Inc. operates the world's only cGMP pulse drying facility for the production of pharmaceutical grade Aquaplex cyclodextrin complexes. The company offers a wide variety of cyclodextrin related manufacturing services to its worldwide customers including: custom formulation, cyclodextrin complex development, and commercial scale supply of pharmaceutical grade cyclodextrin complexes.
About Uno Healthcare
UNO Healthcare is a licensed distributor of pharmaceuticals devoted to licensing pharmaceuticals and acquiring their rights for distribution to countries in Latin America. Our distribution network relies on our experienced sales representatives and our knowledgeable partners located in each country. We source and supply pharmaceuticals to governmental agencies, hospitals, and physicians.
Safe Harbor Statement: This news release contains "forward-looking statements" about the Company's anticipated growth. You are cautioned that such statements are subject to risks and uncertainties and that could cause actual results to differ materially from those projected in the forward-looking statements, such as the Company's ability to obtain additional capital to expand operations as planned. The above forward-looking statements are made as of the date above; CTD Holdings, Inc. accepts no specific responsibility for updating such statements.
Contact:
Investor Relations Contact:Sean MarconiThe WSR Group(772) 219-7525smarconi@thewsrgroup.comhttp://www.wallstreetresources.net/CTDHoldings.asp
Recent CYTH News
- Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results • GlobeNewswire Inc. • 06/14/2024 08:01:00 PM
- Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1 • Business Wire • 05/30/2024 01:00:00 PM
- Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update • Business Wire • 05/16/2024 12:05:00 PM
- Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update • Business Wire • 03/18/2024 01:05:00 PM
- Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease • Business Wire • 03/14/2024 01:34:00 PM
- Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results • GlobeNewswire Inc. • 03/13/2024 09:04:24 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 03/04/2024 09:33:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:46:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:45:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:44:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:43:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:42:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:41:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:40:57 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:44:54 PM
- Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office • Business Wire • 01/29/2024 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 11:01:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 02:50:39 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 02:48:20 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:28:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 01:25:09 AM
- Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc. • Business Wire • 12/27/2023 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:15:21 PM
- Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1 • Business Wire • 12/18/2023 02:15:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 12/18/2023 11:02:37 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM